Price gouging is not in Aspen’s DNA, says founder Stephen Saad, incensed at the thought that his company would exploit the sick. But Aspen’s predicament, and that of all drug firms, boils down to the tension between a drug company’s perceived responsibility to provide life-saving drugs to patients at a reasonable price, and its natural objective to turn a profit
Download (PDF 5.53MB)
Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.
